RxDoctor Payments Data

Katherine Hamilton, MD

Neurology · Chevy Chase, MDNPI 1558603027

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,325 of the $25,593 with a category attached, or 79.4%. 14 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 40.9% of the total. Reporting peaked in 2021 at $10,458 and has fallen 96.0% since, to $422 in 2025.

$25,593in general payments, 2019–2025

Across 70 payments — averaging $365.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$10K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • AbbVie$2K
  • Scilex Pharmaceuticals Inc.$2K
  • Biogen$1K
  • Biodelivery Sciences International, Inc.$1K
  • plus $1K from 8 others
$74,816in research payments, 2019–2025

Across 12 payments — averaging $6234.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$75K

What the payments were for

  • Consulting fees$2,62510%
  • Speaking & faculty fees$20,32579%
  • Travel & lodging$7293%
  • Food & beverage$1,8337%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,593 in reported general payments places this provider in the 85th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$146,064
Medicare patients
94
Services billed
13,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate20$34,700
Emgality PenGalcanezumab-Gnlm36$27,178
Ajovy AutoinjectorFremanezumab-Vfrm16$18,895
UbrelvyUbrogepant12$16,748
Eletriptan HbrEletriptan Hydrobromide28$2,921
Candesartan Cilexetil24$1,241
RizatriptanRizatriptan Benzoate63$1,086
Sumatriptan Succinate19$443
Duloxetine Hcl20$401
Naratriptan Hcl13$382
Topiramate11$344
Memantine Hcl12$327
Gabapentin28$317
Zonisamide12$300
Metoprolol Succinate13$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$383$34,70020 claims
AbbVieUbrelvy$2,184$16,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 neurology providers in Maryland.

Other neurology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →